REKA Stock Overview
Engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rekah Pharmaceutical Industry Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₪15.67 |
52 Week High | ₪17.88 |
52 Week Low | ₪11.67 |
Beta | 0.043 |
11 Month Change | 20.72% |
3 Month Change | 19.53% |
1 Year Change | -3.63% |
33 Year Change | -37.50% |
5 Year Change | -32.37% |
Change since IPO | -95.52% |
Recent News & Updates
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up
Jul 11Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14Recent updates
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up
Jul 11Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Jul 19Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit
Apr 13We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today
Apr 09Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?
Mar 12Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 19Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock
Jan 08How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?
Dec 18Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%
Nov 30Shareholder Returns
REKA | IL Pharmaceuticals | IL Market | |
---|---|---|---|
7D | 3.9% | 0.6% | 0.6% |
1Y | -3.6% | 4.4% | 1.7% |
Return vs Industry: REKA underperformed the IL Pharmaceuticals industry which returned 4.4% over the past year.
Return vs Market: REKA underperformed the IL Market which returned 1.7% over the past year.
Price Volatility
REKA volatility | |
---|---|
REKA Average Weekly Movement | 5.6% |
Pharmaceuticals Industry Average Movement | 5.1% |
Market Average Movement | 4.3% |
10% most volatile stocks in IL Market | 7.4% |
10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: REKA has not had significant price volatility in the past 3 months.
Volatility Over Time: REKA's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1941 | 427 | Mordechai Elgrabli | www.rekah.co.il |
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields.
Rekah Pharmaceutical Industry Ltd. Fundamentals Summary
REKA fundamental statistics | |
---|---|
Market cap | ₪178.87m |
Earnings (TTM) | -₪6.29m |
Revenue (TTM) | ₪332.33m |
0.5x
P/S Ratio-28.5x
P/E RatioIs REKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
REKA income statement (TTM) | |
---|---|
Revenue | ₪332.33m |
Cost of Revenue | ₪249.52m |
Gross Profit | ₪82.81m |
Other Expenses | ₪89.10m |
Earnings | -₪6.29m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.55 |
Gross Margin | 24.92% |
Net Profit Margin | -1.89% |
Debt/Equity Ratio | 86.5% |
How did REKA perform over the long term?
See historical performance and comparison